Oklahoma Health Care Authority

Drug Utilization Review Board
(DUR Board)
Meeting – September 14, 2022 @ 4:00pm
at the
Oklahoma Health Care Authority (OHCA)
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

NOTE: ***The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.***

AGENDA

Discussion and action on the following items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call to Order**

A. Roll Call – Dr. Wilcox

DUR Board Members:

Dr. Stephen Anderson –	participating in person
Dr. Jennifer de los Angeles –	participating in person
Ms. Jennifer Boyett –	participating in person
Dr. Megan Hanner –	participating in person
Dr. Lynn Mitchell –	participating in person
Dr. John Muchmore –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. James Osborne –	participating in person

Viewing Access Only via Zoom:

Please register for the meeting at:
https://zoom.us/webinar/register/WN_73z8ERX7Sv-KeQGP3GVqPg
After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:
Dial: +1-602-753-0140 or +1-669-219-2599
Webinar ID: 952 7560 1667
Passcode: 69395211

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board and completing the Speaker Registration Form. Completed Speaker Registration forms should be submitted to DURPublicComment@okhca.org. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
   A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A**
   A. July 13, 2022 DUR Board Meeting Minutes
   B. July 13, 2022 DUR Board Recommendations Memorandum
   C. August 10, 2022 DUR Board Recommendations Memorandum

Items to be presented by Dr. Moss, Dr. Wilson, Dr. Muchmore, Chairman:

4. **Update on Medication Coverage Authorization Unit/Nonalcoholic Fatty Liver Disease (NAFLD) Overview – See Appendix B**
   A. Pharmacy Helpdesk Activity for August 2022
   B. Medication Coverage Activity for August 2022
   C. NAFLD Overview

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

5. **Action Item – Vote to Update the Approval Criteria for the Ophthalmic Anti-Inflammatory Products – See Appendix C**
   A. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

6. **Action Item – Vote to Prior Authorize Recorlev® (Levoketoconazole) and Update the Approval Criteria for Isturisa® (Osilodrostat) – See Appendix D**
   A. Market News and Updates
   B. Recorlev® (Levoketoconazole) Product Summary

C. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

7. **Action Item – Vote to Prior Authorize Tlando® (Testosterone Undecanoate) and Update the Approval Criteria for the Testosterone Products – See Appendix E**

A. Market News and Updates
B. Cost Comparison
C. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

8. **Action Item – Vote to Update the Approval Criteria for the Opioid Analgesics and Medication-Assisted Treatment (MAT) Medications – See Appendix F**

A. Market News and Updates
B. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

9. **Action Item – Vote to Prior Authorize Adlarity® (Donepezil Transdermal System) and Aduhelm® (Aducanumab-avwa) – See Appendix G**

A. Market News and Updates
B. Aduhelm® (Aducanumab-avwa) Product Summary
C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

10. **Action Item – Vote to Update the Approval Criteria for the Topical Corticosteroids – See Appendix H**

A. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

11. **Action Item – Vote to Prior Authorize Camzyos™ (Mavacamten) – See Appendix I**

A. Market News and Updates
B. Camzyos™ (Mavacamten) Product Summary
C. College of Pharmacy Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

12. **Action Item – Vote to Prior Authorize Alymsys® (Bevacizumab-maly), Lonsurf® (Trifluridine/Tipiracil), and Stivarga® (Regorafenib) and Update the Approval Criteria for the Colorectal Cancer Medications – See Appendix J**

A. Market News and Updates
B. Product Summaries
C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

13. **Action Item – Annual Review of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators – See Appendix K**
    A. Current Prior Authorization Criteria
    B. Utilization of CFTR Modulators
    C. Prior Authorization of CFTR Modulators
    D. Market News and Updates
    E. College of Pharmacy Recommendations
    F. Utilization Details of CFTR Modulators

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

14. **Annual Review of Breast Cancer Medications and 30-Day Notice to Prior Authorize Herceptin Hylecta™ (Trastuzumab/Hyaluronidase-oysk) – See Appendix L**
    A. Introduction
    B. Current Prior Authorization Criteria
    C. Utilization of Breast Cancer Medications
    D. Prior Authorization of Breast Cancer Medications
    E. Market News and Updates
    F. Herceptin Hylecta™ (Trastuzumab/Hyaluronidase-oysk) Product Summary
    G. College of Pharmacy Recommendations
    H. Utilization Details of Breast Cancer Medications

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

15. **Annual Review of Amyloidosis Medications and 30-Day Notice to Prior Authorize Amvuttra™ (Vutrisiran) – See Appendix M**
    A. Current Prior Authorization Criteria
    B. Utilization of Amyloidosis Medications
    C. Prior Authorization of Amyloidosis Medications
    D. Market News and Updates
    E. Amvuttra™ (Vutrisiran) Product Summary
    F. College of Pharmacy Recommendations
    G. Utilization Details of Amyloidosis Medications

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

16. **Annual Review of Synagis® (Palivizumab) – See Appendix N**
    A. Current Prior Authorization Criteria
    B. Utilization of Synagis® (Palivizumab)
    C. Prior Authorization of Synagis® (Palivizumab)
    D. Respiratory Syncytial Virus (RSV) Season Comparison
    E. Market News and Updates
    F. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

17. Annual Review of Nulibry® (Fosdenopterin) – See Appendix O

A. Current Prior Authorization Criteria
B. Utilization of Nulibry® (Fosdenopterin)
C. Prior Authorization of Nulibry® (Fosdenopterin)
D. Market News and Updates
E. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

18. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix P

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

19. Future Business* (Upcoming Product and Class Reviews)

A. Anemia Medications
B. Hepatitis C Medications
C. Spinal Muscular Atrophy (SMA) Medications
D. Targeted Immunomodulator Agents

*Future product and class reviews subject to change.

20. Adjournment

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.